Qualitative
VITROS SARS CoV2 antigen assay – Procedural Steps: –
Stage 1: Nasopharyngeal swab specimen assortment:
1. Purchase a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab until resistance is met on the stage of the turbinate.
3. Rotate the sterile swab plenty of events in direction of the nasopharyngeal wall & go away throughout the place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab sample in VTM to the laboratory in a cold chain.
7. The sample may very well be saved in Room temperature (Beneath 30◦C) for as a lot as 24 hrs from the time of
sample assortment or at 2 – 8◦C for as a lot as 48 hrs from the time of sample assortment.
Diagnostics
1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay meant for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from individuals who
are suspected of COVID-19 inside one to five days of the onset of indicators, or mid-turbinate specimens
collected from asymptomatic individuals.
2. The assay must be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Constructed-in system from Ortho.
Features
COVID-19, Nasopharyngeal swabs
SKU:G61RHA20
AVAILABILITY:In Stock with The Lowest Value throughout the Market
SHIPMENT:Related Day Cargo Orders Sooner than 14
H00SIZE:20 Exams/KitSPECIFICITY:98.90%
Type
Immunochromatography speedy verify
Description
Lateral motion immunochromatographic assay that adopted twin color system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The verify incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the verify traces (T).
A visible black band (antibody-antigen-antibody gold conjugate sophisticated) appears on the verify traces (T) If SARS-CoV-2 antigen is present throughout the specimen.
The administration line (C) reveals that verify is carried out appropriately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %
Guidance for use of VITROS SARS CoV2 Antigen CLIA based Examine from Ortho Medical
Calibration Differ
Stage 2: Sample preparation for testing:
1. Sample preparation should be carried out in BSL-2 stage cabinet throughout the Laboratory.
2. Mix the swab specimen in VTM tube properly (vortex roughly 3-5 seconds).
3. Change 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer proper right into a labelled new sample tube.
4. Add 400 μL viral sample to the above tube (to deal with 1:4 ratio of extraction buffer: sample)
5. Mix properly (Cap/Plug the sample tube and vortex roughly 3-5 seconds).
Biocredit Covid-19 Ag Detection Kit |
|||
| G61RHA20 | RapiGEN | 20 test cards (pkg) | EUR 114 |
COVID-19 Panbio™ COVID-19 Ag Rapid Test Device |
|||
| AF41FK10CFE | Abbott | 25T | EUR 220 |
COVID-19 Ag Rapid Test, Cs |
|||
| R0182C | CTK Biotech | 20 | EUR 1.25 |
COVID-19 Ag Self-Test. Cs |
|||
| R0182CST | CTK Biotech | 1,2,5 | EUR 1.65 |
COVID-19 Ag Rapid Test External Control Kit |
|||
| C0182 | CTK Biotech | each | EUR 520 |
COVID19 Ag LiliF™ GBN COVID-19 Ag Rapid Kit (MFDS Item permission) |
|||
| IRH41071 | iNtRON Biotechnology Inc | 25 Tests/Kit | EUR 75 |
|
Description: Specimens: Nasopharyngeal swabtransport media |
|||
Flu A & Flu B & Covid-19 Ag Rapid Test |
|||
| GF101A3 | Shenzhen Lvshiyuan Biotechnology | 25 Test/kit | Ask for price |
Panbio COVID-19 AG RAPID T Device 25T NP |
|||
| 41FK10 | Abbott | 25 Tests/Kit | EUR 220 |
Panbio COVID-19 AG RAPID T DEVICE 25T NS |
|||
| 41FK11 | Abbott | 25 Tests/Kit | EUR 123.75 |
|
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
|||
COVID-19 + Influenza A. B Ag Rapid Test, Cs |
|||
| R0188C | CTK Biotech | 1fi | Ask for price |
COVID-19 Ag Detection Kit (Colloidal Gold Immunochromatography) |
|||
| MBS398097-20Tests | MyBiosource | 20Tests | EUR 325 |
Truenat™ COVID-19 |
|||
| 601430005 | Molbio Diagnostics Private Limited | 5T | EUR 60 |
Truenat™ COVID-19 |
|||
| 601430020 | Molbio Diagnostics Private Limited | 20T | EUR 240 |
Truenat™ COVID-19 |
|||
| 601430050 | Molbio Diagnostics Private Limited | 50T | EUR 600 |
COVID-19 variant pack |
|||
| SB072 | Smartox Biotechnology | 0.5 | EUR 2325.81 |
|
Description: SARS-CoV-2 Spike (S) glycoprotein:Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein in a class I fusion protein that allows the virus to enter host cells.Variants package available:Some proteins of Sars-CoV-2 are identified as leading targets for COVID-19 therapies. SB-PEPTIDE offers a special pack pre-made peptide libraries of Spike protein including peptides from COVID-19 variants: UK COVID-19 variant B.1.1.7, South Africa COVID-19 variant B.1.351, Brazil COVID-19 variant B.1.1.248. SB-PEPTIDE offers additional plate containing only peptides with Spike S protein mutation of COVID-19 B.1.1.7, B.1.3.5.1 and B.1.1.248 (cited below).Variants package and Spike (S) glycoprotein peptide library can be used for T-cell assays, immune monitoring, antigen specific T-cell stimulation, T-cell expansion and cellular immune response. |
|||
COVID-19 Spike Antigen |
|||
| 30-2018 | Fitzgerald | 1 mg | EUR 400 |
|
Description: COVID-19 Spike recombinant antigen |
|||
COVID-19 Spike Antigen |
|||
| 30-2019 | Fitzgerald | 1 mg | EUR 400 |
|
Description: COVID-19 Spike recombinant antigen |
|||
Moderna COVID-19 Vaccine |
|||
| H7N7-319 | Creative BioMart | 1 vial | EUR 798.4 |
|
Description: Protein |
|||
SARS & COVID-19 coronavirus |
|||
| 3851 | Virostat | 100 ug | EUR 330 |
|
Description: nucleoprotein |
|||
SARS & COVID-19 coronavirus |
|||
| 3861 | Virostat | 100 ug | EUR 330 |
|
Description: nucleoprotein |
|||
SARS & COVID-19 coronavirus |
|||
| 3862 | Virostat | each | EUR 330 |
|
Description: nucleoprotein |
|||
SARS & COVID-19 coronavirus |
|||
| 3863 | Virostat | each | EUR 330 |
|
Description: nucleoprotein |
|||
SARS & COVID-19 coronavirus |
|||
| 3864 | Virostat | each | EUR 330 |
|
Description: nucleoprotein |
|||
COVID-19 Negative Control |
|||
| MBS412771-05mL | MyBiosource | 0.5mL | EUR 100 |
COVID-19 Negative Control |
|||
| MBS412771-5x05mL | MyBiosource | 5x0.5mL | EUR 305 |
COVID-19 Nucleocapsid protein |
|||
| 30-2005 | Fitzgerald | 1 mg | EUR 700 |
|
Description: COVID-19 Nucleocapsid protein recombinant antigen |
|||